Journal of Diagnostics Concepts & Practice ›› 2026, Vol. 25 ›› Issue (03): 327-336.doi: 10.16150/j.1671-2870.2026.03.009
• Original articles • Previous Articles Next Articles
DOU Jianminga, WU Chunxiaoa,*, CHEN Leib, PANG Yia, SHI Yanc(
), GU Kaia(
)
Received:2025-12-10
Revised:2026-02-08
Accepted:2026-02-10
Online:2026-06-25
Published:2026-06-27
Contact:
SHI Yan, GU Kai
E-mail:shiyan@scdc.sh.cn;gukai@scdc.sh.cn
CLC Number:
DOU Jianming, WU Chunxiao, CHEN Lei, PANG Yi, SHI Yan, GU Kai. Incidence and mortality analysis of lung cancer in Shanghai from 2002 to 2019[J]. Journal of Diagnostics Concepts & Practice, 2026, 25(03): 327-336.
Table 1
Incidence and mortality of lung cancer in Shanghai, 2019
| Category | Gender | Rank | Number | Proportion /% | Crude rate /10-5 | ASR1 /10-5 | TASR2 /10-5 | Cumulative rate /% | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 35-64 years | 0-64 years | 0-74 years | 0-84 years | |||||||
| Incidence | Both | 1 | 21 835 | 23.80 | 148.87 | 63.82 | 107.90 | 3.81 | 7.83 | 11.54 |
| Male | 1 | 12 010 | 25.28 | 165.48 | 66.37 | 94.74 | 3.42 | 8.36 | 13.72 | |
| Female | 1 | 9 825 | 22.20 | 132.60 | 62.09 | 120.96 | 4.20 | 7.30 | 9.66 | |
| Mortality | Both | 1 | 9 573 | 25.25 | 65.27 | 21.75 | 20.96 | 0.77 | 2.58 | 5.58 |
| Male | 1 | 6 919 | 29.37 | 95.33 | 33.50 | 30.96 | 1.16 | 3.96 | 8.73 | |
| Female | 1 | 2 654 | 18.49 | 35.82 | 10.95 | 11.09 | 0.40 | 1.20 | 2.75 | |
Table 2
Trends of age-specific rates of incidence of lung cancer in Shanghai, stratified by gender, 2002-2019
| Age group/year | 2002 Rates(1/105) | Joinpoint | 2019 Rates(1/105) | Trend 1 | Trend 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | Rates(1/105) | Years | APC | t value | P value | Years | APC | t value | P value | ||||
| Male | |||||||||||||
| 20- | 0.43 | 2012 | 0.47 | 3.66 | 2002-2012 | -1.89 | -0.91 | 0.388 | 2012-2019 | 38.31 | 13.66 | <0.001 | |
| 25- | 0.75 | 2008 | 0.18 | 6.48 | 2002-2008 | -9.83 | -0.78 | 0.450 | 2008-2019 | 26.88 | 8.42 | <0.001 | |
| 30- | 2.97 | 2009 | 1.27 | 11.74 | 2002-2009 | -18.19 | -4.1 | 0.001 | 2009-2019 | 29.39 | 14.18 | <0.001 | |
| 35- | 5.99 | 2014 | 4.08 | 20.74 | 2002-2014 | -2.17 | -1.38 | 0.191 | 2014-2019 | 35.58 | 8.13 | <0.001 | |
| 40- | 15.98 | 2011 | 9.29 | 36.51 | 2002-2011 | -5.44 | -2.95 | 0.011 | 2011-2019 | 15.77 | 6.86 | <0.001 | |
| 45- | 33.66 | - | - | 48.67 | 2002-2019 | 1.77 | 3.64 | 0.002 | |||||
| 50- | 60.65 | - | - | 84.84 | 2002-2019 | 2.31 | 7.12 | <0.001 | |||||
| 55- | 116.51 | - | - | 176.50 | 2002-2019 | 3.66 | 8.57 | <0.001 | |||||
| 60- | 197.98 | 2013 | 177.80 | 292.84 | 2002-2013 | -0.68 | -1.12 | 0.285 | 2013-2019 | 9.55 | 9.49 | <0.001 | |
| 65- | 322.43 | - | - | 432.01 | 2002-2019 | 1.39 | 1.99 | 0.064 | |||||
| 70- | 503.26 | - | - | 556.68 | 2002-2019 | 0.17 | 0.33 | 0.747 | |||||
| 75- | 654.84 | 2011 | 510.15 | 582.61 | 2002-2011 | -2.30 | -4.41 | 0.001 | 2011-2019 | 0.78 | 1.26 | 0.230 | |
| 80- | 664.05 | 2009 | 639.08 | 489.54 | 2002-2009 | -0.04 | -0.06 | 0.955 | 2009-2019 | -2.47 | -6.73 | <0.001 | |
| ≥85 | 534.70 | 587.53 | 2002-2019 | -0.22 | -0.70 | 0.495 | |||||||
| Female | |||||||||||||
| 20- | 0.23 | 2010 | 0.20 | 6.06 | 2002-2010 | -11.97 | -0.92 | 0.381 | 2010-2019 | 43.24 | 6.19 | <0.001 | |
| 25- | 0.54 | 2011 | 1.14 | 19.16 | 2002-2011 | 8.03 | 1.31 | 0.211 | 2011-2019 | 45.20 | 13.48 | <0.001 | |
| 30- | 2.18 | 2010 | 1.70 | 36.63 | 2002-2010 | -5.45 | -1.28 | 0.221 | 2010-2019 | 41.53 | 20.52 | <0.001 | |
| 35- | 5.13 | 2012 | 6.68 | 56.96 | 2002-2012 | 4.23 | 1.23 | 0.241 | 2012-2019 | 38.88 | 12.48 | <0.001 | |
| 40- | 10.24 | 2012 | 12.45 | 91.64 | 2002-2012 | 3.21 | 1.89 | 0.081 | 2012-2019 | 32.45 | 17.05 | <0.001 | |
| 45- | 18.14 | 2010 | 16.58 | 110.24 | 2002-2010 | 0.53 | 0.31 | 0.762 | 2010-2019 | 22.54 | 19.61 | <0.001 | |
| 50- | 31.05 | 2009 | 30.96 | 123.20 | 2002-2009 | -0.14 | -0.07 | 0.944 | 2009-2019 | 15.72 | 18.41 | <0.001 | |
| 55- | 47.67 | 2010 | 45.42 | 175.50 | 2002-2010 | 1.10 | 0.80 | 0.440 | 2010-2019 | 14.90 | 22.20 | <0.001 | |
| 60- | 63.13 | 2011 | 75.70 | 219.69 | 2002-2011 | 1.49 | 0.76 | 0.459 | 2011-2019 | 14.72 | 12.06 | <0.001 | |
| 65- | 101.49 | 2013 | 113.55 | 288.16 | 2002-2013 | 0.73 | 0.57 | 0.578 | 2013-2019 | 17.11 | 8.40 | <0.001 | |
| 70- | 164.23 | 332.39 | 2002-2019 | 4.45 | 5.29 | <0.001 | |||||||
| 75- | 196.79 | - | - | 264.90 | 2002-2019 | 1.75 | 4.56 | <0.001 | |||||
| 80- | 221.31 | - | - | 206.51 | 2002-2019 | -0.14 | -0.49 | 0.628 | |||||
| ≥85 | 166.28 | - | - | 263.13 | 2002-2019 | 1.30 | 4.44 | <0.001 | |||||
Table 3
Trends of age-specific rates of mortality of lung cancer in Shanghai, stratified by gender, 2002-2019
| Age group/year | 2002 Rates(1/105) | Joinpoint | 2019 Rates (1/105) | Trend 1 | Trend 2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | Rates(1/105) | Years | APC | t value | P value | Years | APC | t value | P value | |||||
| Male | ||||||||||||||
| 30- | 1.37 | - | - | 1.07 | 2002-2019 | -5.52 | -3.04 | 0.008 | ||||||
| 35- | 2.27 | - | - | 1.41 | 2002-2019 | -2.89 | -2.46 | 0.025 | ||||||
| 40- | 10.70 | - | - | 4.11 | 2002-2019 | -4.71 | -4.92 | <0.001 | ||||||
| 45- | 24.54 | 2013 | 19.49 | 6.89 | 2002-2013 | -1.22 | -1.51 | 0.155 | 2013-2019 | -12.48 | -4.08 | 0.001 | ||
| 50- | 36.98 | 2014 | 49.04 | 18.29 | 2002-2014 | 2.92 | 4.38 | 0.001 | 2014-2019 | -15.67 | -5.64 | <0.001 | ||
| 55- | 85.93 | - | - | 61.51 | 2002-2019 | 0.80 | 1.28 | 0.219 | ||||||
| 60- | 138.73 | - | - | 136.99 | 2002-2019 | 0.65 | 2.21 | 0.042 | ||||||
| 65- | 254.10 | - | - | 220.70 | 2002-2019 | -0.8 | -2.05 | 0.057 | ||||||
| 70- | 439.48 | - | - | 339.90 | 2002-2019 | -1.32 | -4.22 | 0.001 | ||||||
| 75- | 640.52 | - | - | 453.04 | 2002-2019 | -1.70 | -9.55 | <0.001 | ||||||
| 80- | 759.46 | - | - | 500.79 | 2002-2019 | -1.73 | -5.58 | <0.001 | ||||||
| ≥85 | 688.67 | - | - | 663.36 | 2002-2019 | -0.33 | -0.91 | 0.374 | ||||||
| Female | ||||||||||||||
| 30- | 1.21 | - | - | 0.73 | 2002-2019 | -4.28 | -2.28 | 0.037 | ||||||
| 35- | 3.59 | - | - | 1.04 | 2002-2019 | -3.63 | -3.21 | 0.005 | ||||||
| 40- | 5.12 | - | - | 3.77 | 2002-2019 | -1.67 | -1.75 | 0.099 | ||||||
| 45- | 12.94 | - | - | 6.98 | 2002-2019 | -1.64 | -2.43 | 0.027 | ||||||
| 50- | 18.76 | - | - | 8.97 | 2002-2019 | -1.52 | -1.85 | 0.083 | ||||||
| 55- | 34.41 | - | - | 21.60 | 2002-2019 | -2.11 | -3.65 | 0.002 | ||||||
| 60- | 53.91 | - | - | 35.46 | 2002-2019 | -1.35 | -3.03 | 0.008 | ||||||
| 65- | 79.22 | - | - | 61.65 | 2002-2019 | -1.61 | -6.11 | <0.001 | ||||||
| 70- | 146.06 | - | - | 99.31 | 2002-2019 | -1.62 | -3.72 | 0.002 | ||||||
| 75- | 185.27 | 2014 | 183.85 | 130.35 | 2002-2014 | 0.14 | 0.22 | 0.829 | 2014-2019 | -6.45 | -2.58 | 0.023 | ||
| 80- | 213.82 | 2014 | 228.37 | 180.50 | 2002-2014 | 1.00 | 2.35 | 0.035 | 2014-2019 | -4.97 | -3.66 | 0.003 | ||
| ≥85 | 202.78 | - | - | 277.22 | 2002-2019 | 1.33 | 4.23 | <0.001 | ||||||
Table 4
Trends of proportions of lung cancer in Shanghai, stratified by selected diagnostic characters, 2002-2019
| Category | 2002 Percentage/% | Joinpoint | 2019 Percentage/% | Trend 1 | Trend 2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | Percentage/% | Years | APC | t value | P value | Years | APC | t value | P value | |||||
| Diagnostic basis | ||||||||||||||
| Morphological verification | 44.28 | 61.88 | 2002-2019 | 3.12 | 9.29 | <0.001 | ||||||||
| Imaging verification | 41.50 | 2008 | 30.51 | 7.99 | 2002-2008 | -4.80 | -4.15 | 0.001 | 2008-2019 | 10.83 | -24.25 | <0.001 | ||
| Others | 14.22 | 30.14 | 2002-2019 | 1.62 | 2.24 | 0.040 | ||||||||
| Anatomic site | - | - | ||||||||||||
| Trachea, bronchus | 3.32 | - | - | 0.22 | 2002-2019 | -19.82 | -14.91 | <0.001 | ||||||
| Pulmonary lobes | 35.89 | - | - | 24.12 | 2002-2019 | -3.09 | -10.95 | <0.001 | ||||||
| Unspecified | 60.79 | - | - | 75.65 | 2002-2019 | 1.67 | 13.55 | <0.001 | ||||||
| Histological type | - | - | ||||||||||||
| Adenocarcinoma | 19.66 | - | - | 41.20 | 2002-2019 | 5.85 | 13.48 | <0.001 | ||||||
| Squamous-cell carcinoma | 14.13 | 2010 | 12.43 | 6.29 | 2002-2010 | -0.25 | -0.33 | 0.746 | 2010-2019 | -7.18 | -11.92 | <0.001 | ||
| Others | 4.03 | 2011 | 8.79 | 6.62 | 2002-2011 | 9.06 | 11.15 | <0.001 | 2011-2019 | -2.57 | -2.80 | 0.015 | ||
| Unspecified | 62.17 | - | - | 45.89 | 2002-2019 | -3.16 | -8.18 | <0.001 | ||||||
| Stage | - | - | ||||||||||||
| Ⅰ | 3.76 | 2010 | 6.38 | 22.60 | 2002-2010 | 8.32 | 5.87 | <0.001 | 2010-2019 | 16.46 | 13.36 | <0.001 | ||
| Ⅱ | 5.67 | 2010 | 4.94 | 2.59 | 2002-2010 | -1.33 | -1.14 | 0.227 | 2010-2019 | -7.14 | -7.50 | <0.001 | ||
| Ⅲ | 14.52 | 2009 | 13.62 | 4.88 | 2002-2009 | -0.79 | -1.03 | 0.321 | 2009-2019 | -9.24 | -21.79 | <0.001 | ||
| Ⅳ | 21.14 | 2011 | 30.51 | 15.88 | 2002-2011 | 4.76 | 11.09 | <0.001 | 2011-2019 | -7.61 | -15.80 | <0.001 | ||
| Unknown | 54.92 | 2010 | 47.65 | 54.05 | 2002-2010 | -2.41 | -5.19 | <0.001 | 2010-2019 | 1.33 | 3.37 | 0.005 | ||
| [1] | BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. |
| [2] | HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53. |
| [3] | 顾凯, 庞怡, 吴春晓, 等. 2017年上海市恶性肿瘤发病和死亡情况与2002-2017年的变化趋势分析[J]. 肿瘤, 2023, 43(4):241-256. |
| GU K, PANG YM WU C X. Analysis of the current status of cancer incidence and mortality in Shanghai,2017 and trends of 2002-2017[J]. Tumor, 2023, 43(4):241-256. | |
| [4] | 国家癌症中心. 中国肿瘤登记工作指导手册[M].人民卫生出版社, 2016. |
| National Cancer Center. Chinese guideline for cancer regi-stration[M]. People's Medical Publishing House, 2016. | |
| [5] | PARKIN D M, CHEN V W, FERLAY J, et al. Comparability and quality control in cancer registration. IARC Technical Report No.19[M]. Lyon: IARC Press,1994. |
| [6] | 上海市疾病预防控制中心. 上海市恶性肿瘤发病率、死亡率和生存率(2001-2012)[M] 上海: 上海科学普及出版社,2017:1-6. |
| Shanghai Municipal Center For Disease Control & Prevention. Cancer incidence, mortality and survival rates in Shanghai (2001-2012)[M]. Shanghai: Shanghai General Science Press,2017:1-6. | |
| [7] | TRAVIS W D, BRAMBILLA E, BURKE A P, et al. WHO classification of tumours of the lung, pleura, thymus and heart[M]. Geneva: WHO Press, 2015. |
| [8] | 卢伟, 郑莹. 肿瘤命名与编码[M]. 上海: 第二军医大学出版社, 2011. |
| LU W, ZHENG Y. Tumor nomenclature and coding[M]. Shanghai: Second Military Medical University Press, 2011. | |
| [9] | SEGI M, NIPPON T K, TŌHOKU D I. Cancer mortality for selected sites in 24 countries (1950-1957)[M]. Sendai, Japan: Japan Cancer Society,1960. |
| [10] | Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, Version 4.8.0.1[CP]. April, 2020. |
| [11] |
KIM H J, FAY M P, FEUER E J, et al. Permutation tests for joinpoint regression with applications to cancer rates[J]. Statist Med, 2000, 19(3):335-351.
doi: 10.1002/(ISSN)1097-0258 URL |
| [12] | 窦剑明, 吴春晓, 庞怡, 等. 2016年上海市肺癌发病和死亡的特征及其在2002-2016年的变化趋势[J]. 肿瘤, 2023, 43(4):266-276. |
| DOU J M, WU C X, PANG Y, et al. The incidence and mortality of lung cancer in 2016 and their trends from 2002 to 2016 in Shanghai[J]. Tumor, 2023, 43(4): 266-276. | |
| [13] |
XIE D, ZHANG L, HE N, et al. Overdiagnosis of lung cancer due to the introduction of low-dose computed tomography in average-risk populations in the people’s republic of China[J]. J Thorac Oncol, 2025, 20(7):884-896.
doi: 10.1016/j.jtho.2025.02.013 URL |
| [14] |
National Lung Screening Trial Research Team, ABERLE D R, ADAMS A M, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5):395-409.
doi: 10.1056/NEJMoa1102873 URL |
| [15] |
ZHOU Q, FAN Y, WU N, et al. Demonstration program of population-based lung cancer screening in China: Rationale and study design[J]. Thorac Cancer, 2014, 5(3):197-203.
doi: 10.1111/1759-7714.12078 pmid: 26767001 |
| [16] |
LUO X, ZHENG S, LIU Q, et al. Should nonsmokers be excluded from early lung cancer screening with low-dose spiral computed tomography? Community-based practice in Shanghai[J]. Transl Oncol, 2017, 10(4):485-490.
doi: S1936-5233(17)30019-0 pmid: 28521182 |
| [17] | YANG W, QIAN F, TENG J, et al. Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening[J]. Lung Cancer, 2018,117:20-26. |
| [18] | LIANG F, WU C, GU H, et al. Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screening[J]. Lung Cancer, 2019,132:114-118. |
| [19] |
张敏璐, 吴春晓, 龚杨明, 等. 上海人群肺癌生存率分析[J]. 中国癌症杂志, 2017, 27(5):326-333.
doi: 10.19401/j.cnki.1007-3639.2017.05.002 |
|
ZHANG M L, WU C X, GONG Y M, et al. Survival analysis of patients with lung cancer in Shanghai[J]. Chin Oncol, 2017, 27(5):326-333.
doi: 10.19401/j.cnki.1007-3639.2017.05.002 |
|
| [20] |
SACHER A G, DAHLBERG S E, HENG J, et al. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer[J]. JAMA Oncol, 2016, 2(3):313.
doi: 10.1001/jamaoncol.2015.4482 pmid: 26720421 |
| [21] |
KO Y H, KIM S J, KIM W S, et al. Risk factors for primary lung cancer among never-smoking women in South Korea: A retrospective nationwide population-based cohort study[J]. Korean J Intern Med, 2020, 35(3):692-702.
doi: 10.3904/kjim.2019.283 pmid: 32066220 |
| [22] |
WU X, ZHU B, ZHOU J, et al. The epidemiological trends in the burden of lung cancer attributable to PM2.5 exposure in China[J]. BMC Public Health, 2021, 21(1):737.
doi: 10.1186/s12889-021-10765-1 |
| [23] |
FUENTES N, SILVA RODRIGUEZ M, SILVEYRA P. Role of sex hormones in lung cancer[J]. Exp Biol Med (Maywood), 2021, 246(19):2098-2110.
doi: 10.1177/15353702211019697 URL |
| [24] |
MIRANDA-FILHO A, PIÑEROS M, BRAY F. The descriptive epidemiology of lung cancer and tobacco control: a global overview 2018[J]. Salud Publica Mex, 2019; 61(3):219-229.
doi: 10.21149/10140 URL |
| [25] | SONG M A, BENOWITZ N L, BERMAN M, et al. Cigarette filter ventilation and its relationship to increasing rates of lung adenocarcinoma[J]. JNCI J Natl Cancer Inst, 2017, 109(12):djx075. |
| [26] | LUO W, ZENG Z, JIN Y, et al. Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers[J]. Cell Rep Med, 2023, 4(6):101078. |
| [27] |
SUN Y, REN Y, FANG Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases[J]. J Clin Oncol, 2010, 28(30):4616-4620.
doi: 10.1200/JCO.2010.29.6038 pmid: 20855837 |
| [28] |
CHEN J, YANG H, TEO A S M, et al. Genomic landscape of lung adenocarcinoma in East Asians[J]. Nat Genet, 2020, 52(2):177-186.
doi: 10.1038/s41588-019-0569-6 pmid: 32015526 |
| [29] | MIDHA A, DEARDEN S, MCCORMACK R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethni-city (mutMapⅡ). Am J Cancer Res. 2015; 5(9):2892-2911. |
| [30] |
LEITER A, VELUSWAMY R R, WISNIVESKY J P. The global burden of lung cancer: Current status and future trends[J]. Nat Rev Clin Oncol, 2023, 20(9):624-639.
doi: 10.1038/s41571-023-00798-3 pmid: 37479810 |
| [31] | 郑杨, 王春芳, 吴春晓, 等. 《“健康上海2030”规划纲要》三项主要指标解读[J]. 上海预防医学, 2018, 30(1):11-14,20. |
| ZHENG Y, WANG C F, WU C X, et al. Interpretation of three main indicators of the "2030 Plan for Healthy Shanghai"[J]. Shanghai J Prev Med, 2018, 30(1):11-14,20. |
| [1] | CAI Jiaodi, CHEN Guoqun, ZHANG Wenqin. Interpretation of the 2025 NCCN clinical practice guidelines for non-small cell lung cancer (V1-V3) [J]. Journal of Diagnostics Concepts & Practice, 2026, 25(01): 37-43. |
| [2] | XIE Xiangmei, HAN Ying, SU Juan, HENG Wei. A case report of seminal vesicle metastasis from lung cancer [J]. Journal of Diagnostics Concepts & Practice, 2026, 25(01): 96-99. |
| [3] | WU Qi, FAN Bonan, LI Yan. Analysis and interpretation of the 2022 Global Cancer Statistics Report: cancer burden and epidemiological trends in China and the world [J]. Journal of Diagnostics Concepts & Practice, 2025, 24(02): 135-145. |
| [4] | CHEN Weiwei, SUN Liangdan. Research progress in genetic epidemiology of psoriasis in Chinese population [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(06): 561-567. |
| [5] | FAN Bonan, LI Yan. Trends in global major disease burden and health conditions—interpretation of the Global Burden of Disease Study 1990-2021 [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(05): 474-483. |
| [6] | ZHANG Zhiping, CAI Shilong, GENG Yanlong, LIU Shiyou. Analysis of incidence trend of thyroid cancer in Baoshan District, Shanghai from 2000 to 2022 [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 378-384. |
| [7] | ZHANG Xin, ZHENG Ying. Interpretation of cancer death burden data from disease surveillance sites in China from 2005 to 2020 [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 371-377. |
| [8] | WANG Gang, QI Jinlei, LIU Xinya, REN Rujing, LIN Shaohui, HU Yisong, LI Haixia, XIE Xinyi, WANG Jintao, LI Jianping, ZHU Yikang, GAO Mengyi, YANG Junjie, WANG Yiran, JING Yurong, GENG Jieli, ZHI Nan, CAO Wenwei, XU Qun, YU Xiaoping, ZHU Yuan, ZHOU Ying, WANG Lin, GAO Chao, LI Binyin, CHEN Shengdi, YUAN Fang, DOU Ronghua, LIU Xiaoyun, LI Xuena, YIN Yafu, CHANG Yan, XU Gang, XIN Jiawei, ZHONG Yanting, LI Chunbo, WANG Ying, ZHOU Maigeng, CHEN Xiaochun, representing the China Alzheimer's Disease Report Writing Group . China Alzheimer Report 2024 [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(03): 219-256. |
| [9] | ZHANG Dongyan, LI Yan. Summary and interpretation of the World Health Organization “Global Report on Hypertension” [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(03): 297-304. |
| [10] | HUANG Rui, RAO Huiying. Current status, screening and diagnostic strategies for hepatitis C virus infection in the context of “elimination” [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(01): 1-8. |
| [11] | ZHANG Ying, JIANG Xiaofei. Analysis of global burden of bacterial infections: an interpretation of Global mortality associated with 33 bacterial pathogens in 2019 [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(06): 541-549. |
| [12] | ZHAN Dui, NIMA Zhuoma, DOU Ji, PINGCUO Zhuoma, QI Jinlei. Analysis of all-cause mortality data of residents in Shannan City, Tibet, 2021 [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(06): 562-566. |
| [13] | FAN Zhenjia, ZHAO Juntao, ZHOU Jiakuan, LI Zhanquan, WAN Yinglei. Application value of ST2 combined with CEA and CYFRA211 in diagnosis of early non-small cell lung cancer [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(05): 441-447. |
| [14] | SHI Yuling, CHEN Wenjuan. Psoriasis comorbidity: prevalence, diagnosis and treatment [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(03): 221-229. |
| [15] | TANG Chunhua, GUO Lu, LI Qiong, ZHANG Lili. Interpretation on the report of global stroke data 2022 [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(03): 238-246. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||